Fosun Pharmaceutical Faces Market Skepticism Over $200 Million Green Valley Acquisition Amid Regulatory Concerns
核心洞察
Fosun Pharmaceutical announced plans to acquire a controlling stake in Green Valley Technology for 1.412 billion yuan ($200 million), developer of the controversial Alzheimer's drug GV-971.
The market reacted negatively with Fosun's shares falling nearly 10% following the announcement, reflecting investor concerns about Green Valley's troubled regulatory history.
GV-971 was pulled from production in 2024 after Green Valley failed to submit required confirmatory clinical trial data to Chinese regulators, despite generating over 600 million yuan in sales.
Fosun Pharmaceutical announced on December 15 its intention to acquire a controlling stake in Green Valley Technology for 1.412 billion yuan ($200 million), marking a controversial bet on the Chinese developer of sodium oligomannate (GV-971), promoted as China's first homegrown Alzheimer's disease treatment. The market's immediate response was harsh, with Fosun's shares plummeting nearly 10% following the announcement.
The acquisition comes at a challenging time for Green Valley, whose flagship product GV-971 was pulled from production by the end of 2024 after the company failed to submit required confirmatory clinical trial data to the National Medical Products Administration (NMPA). According to regulatory requirements, the confirmatory data needed to be "randomized, double-blind, multicenter" to maintain the drug's conditional approval status.
Troubled Regulatory History
Green Valley's reputation extends far beyond current concerns about GV-971's efficacy. The company has faced decades of regulatory scrutiny, beginning with its earlier flagship product "Shuangling Guben San" (formerly marketed as "China Lingzhi Bao"). Between 2001 and 2006, this product appeared in national-level unlawful drug advertising bulletins over 800 times, according to Chinese state media reports.
In 2007, the State Administration for Industry and Commerce specifically cited Green Valley and its affiliated companies for multiple regulatory violations. Shanghai industrial and commercial authorities alone investigated and closed 12 cases of illegal advertising regarding "Shuangling Guben San" in a single year, imposing fines totaling 890,000 yuan.
The NMPA ultimately revoked approval for Shuangling Guben San on April 28, 2007, citing that "the clinical trial data were not authentic and the promotional content went beyond the approved scope of functions and indications." The company was also found to have fabricated promotional materials, including forging issues of state-run newspapers for distribution in hospitals and pharmacies.
GV-971's Controversial Journey
GV-971 received conditional approval from the NMPA in 2019, despite opposition from numerous experts including Rao Yi, then president of Capital Medical University. Critics questioned the drug's effectiveness, arguing that its benefits were not obvious and trial periods were too short.
Neuroscientist Rao Yi, writing in Cell Research, highlighted concerns about the drug's purported mechanisms, noting that earlier publications attributed to GV-971 "a long list of disparate mechanisms and targets." Rao added: "I have never come across a single drug with so many targets for curing or alleviating one disease."
Despite the scientific controversy, GV-971 achieved significant commercial success. In 2023, the drug sold 2.3 million boxes with sales exceeding 600 million yuan and was included in China's national medical insurance reimbursement list.
Failed International Expansion
Green Valley's ambitions extended beyond China, with the company applying to the U.S. Food and Drug Administration for a Phase III clinical trial. However, in 2022, the company announced it was halting these efforts, citing lack of funding as the primary reason.
The funding shortage stands in stark contrast to the drug's commercial performance in China. As one industry observer noted, "GV-971 can sell more than 600 million yuan worth in a single year, but whether this drug actually works is a question that I don't know—what we do know is that an effective medicine never runs out of money."
Expanding Claims and Scientific Concerns
Green Valley continues to promote GV-971 for additional indications beyond Alzheimer's disease. The company now advertises research findings published in Nature Communications regarding GV-971's potential for treating severe acute pancreatitis. However, the actual study reported GV-971 "as being a protective agent in various male mouse SAP models"—a significant gap from proven human therapeutic applications.
The company's website currently promotes GV-971 for treating acute pancreatitis and inhibiting peripheral inflammation, expanding beyond its original Alzheimer's indication despite the lack of regulatory approval for these uses.
Key Players and Conflicts of Interest
The development of GV-971 involved several prominent figures from China's pharmaceutical research community. Researcher Geng Meiyu from the Shanghai Institute of Materia Medica developed the drug, which caught the attention of Green Valley founder Lv Songtao. According to company statements, Lv borrowed $500,000 and signed an $80 million contract to secure the patent rights.
Ding Jian, former director of the Shanghai Institute of Materia Medica, played a key role in connecting the parties and later became involved with Green Valley. After leaving the institute, Ding founded Haihe Biopharma, which attempted but failed to list on China's STAR Market in 2021 due to questions about its R&D capabilities.
Geng Meiyu succeeded Ding as director of the Shanghai Institute of Materia Medica and became a shareholder of Green Valley. In 2024, she became a candidate for election as an Academician of the Chinese Academy of Sciences, with Ding Jian serving as her nominator.
Market and Regulatory Outlook
Fosun Pharmaceutical has stated its intention to restart halted trials and eventually return GV-971 to the market. However, the acquisition still requires regulatory approval, and the drug's clinical data remains under scrutiny.
The immediate market reaction suggests significant investor skepticism about the deal's prospects. The 10% share price decline reflects concerns not only about GV-971's scientific validity but also about the reputational risks associated with Green Valley's troubled regulatory history.
The acquisition represents a significant test for both companies, as they navigate the complex landscape of Alzheimer's drug development—a field where major pharmaceutical companies worldwide have invested over $600 billion across more than 300 drug candidates, with notably high failure rates.